A Phase 3 interventional study of Pramipexole and Placebo in Restless Legs Syndrome, sponsored by Boehringer Ingelheim. Completed at 16 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-06-09.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing pramipexole in Restless Legs Syndrome — none open to participants now, 1 under way, none of them phase 3. Pramipexole · Restless Legs Syndrome.
Among the 17 studies testing pramipexole in Restless Legs Syndrome, this one is the 7th largest by enrollment, is the only one that started in 2008, is one of 6 in phase 3, and was the 13th registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →None of the 17 studies testing pramipexole in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →
Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 7 · Phase 4 8
First in 2002; this study’s year is marked. 1 started in 2008.
This study's enrollment of 306 is above the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 154 across the 17 interventional studies. Of the 16 that completed or were terminated, 4 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 5 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
21 studies in Restless Legs Syndrome by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 21 finished, 8 (38%) have results posted.
Among the 21 studies in Restless Legs Syndrome by Boehringer Ingelheim, this one is the 7th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2008, is one of 6 in phase 3, and was the 14th registered.
Boehringer Ingelheim’s Restless Legs Syndrome studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing pramipexole in Restless Legs Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 21 in Restless Legs Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine efficacy and safety of Pramipexole 0.125mg to 0.75mg daily for 6 weeks compared to placebo in the treatment of idiopathic Restless Legs Syndrome (RLS)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of idiopathic Restless Legs Syndrome (IRLS) according to the clinical Restless Legs Syndrome (RLS) criteria of the International Restless Legs Syndrome Study Group (IRLSSG)
All four criteria must be present to fulfil the diagnosis of RLS:
Exclusion Criteria:
Concomitant or previous pharmacologically therapy of RLS as follows:
Any of the following lab results at screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 weeks of individual dose titration starting with Pramipexole 0.125 mg, next dose steps 0.25 mg, 0.5 mg and 0.75 mg, fixed dose for 2 weeks, once daily
Drug: Pramipexole
4 weeks of individual dose titration as for the investigational product, once daily
Drug: Placebo
The Change From Baseline to Week 6 in the Total Score of Restless Legs Syndrome Rating Scale for Severity of the International Restless Legs Syndrome Study Group (IRLS).
The IRLS was a 10-item self patient's rating scale for assessing severity of restless legs syndrome symptoms with each item ranging from 0 (no symptoms) to 4 (very severe symptoms). The total IRLS score ranges from 0 (no symptoms) to 40 (worst possible symptoms).
Time frame: Baseline and 6 weeks of treatment
The Proportion of Patients With Clinical Global Impressions -Improvement Scale (CGI-I) Assessment of "Much Improved" and "Very Much Improved"
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved)and 2 (much improved.
Time frame: 6 weeks of treatment
The Proportion of IRLS Responders
responders is defined as the total score in IRLS changed ≥ 50%from baseline calculated in the full analysis set population.
Time frame: 6 weeks of treatment
The Proportion of Patient Global Impression(PGI) Responders
PGI was a one-question scale with 7 degrees to assess patient's overall condition, ranging from very much better to very much worse. The responder are defined as patients with their assessment of "much better" or "very much better".
Time frame: 6 weeks of treatment
The Proportion of Patients With Epworth Sleepiness Scale (ESS) Categorised >10
The ESS is a self-administered instrument to assess the patients likelihood of falling asleep in various activities of daily living; the maximum score is 24 indicating a very high level of daytime sleepiness and a high likelihood of falling asleep.
Time frame: week 6 of treatment
the Mean Change From Baseline to Week 6 in Satisfaction of Sleep at Night of RLS-6 Rating Scales
RLS-6 rating scales comprises 6 questions Satisfaction of sleep is one of the 6 questions. The patient should give a rate between 0 (none/Not at all) to 10 (very severe) for the satisfaction of sleep.
Time frame: Baseline and 6 weeks of treatment
The Mean Change From Baseline in the Severity of RLS at Time of Falling Sleep of RLS-6 Rating Scales.
RLS-6 rating scales comprises 6 questions. The severity of RLS at time of falling sleep is one of the 6 questions. The patient should give a rate between 0 (none/Not at all) to 10 (very severe) for the severity of RLS at time of falling sleep
Time frame: Baseline and 6 weeks of treatment
The Mean Change From Baseline in the Severity of RLS During the Night of RLS-6 Rating Scales.
RLS-6 rating scales comprises 6 questions. The severity of RLS during the night is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the severity of RLS during the night.
Time frame: Baseline and 6 weeks of treatment
The Mean Change From Baseline in the Severity of RLS During the Rest at Day of RLS-6 Rating Scales.
RLS-6 rating scales comprises 6 questions. The severity of RLS during the test at day is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the severity of RLS during the rest at day.
Time frame: Baseline and 6 weeks of treatment
The Mean Change From Baseline in the Severity of RLS During the Activities at Day of RLS-6 Rating Scale
RLS-6 rating scales comprises 6 questions. The severity of RLS during the activities at day is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the severity of RLS during the activity at day.
Time frame: Baseline and 6 weeks of treatment
The Mean Change From Baseline in the Intensity of Tiredness and Sleepiness at Day of RLS-6 Rating Scale
RLS-6 rating scales comprises 6 questions. The intensity of tiredness and sleepiness at day is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the intensity of tiredness and sleepiness at day.
Time frame: Baseline and 6 weeks of treatment
The Change From Baseline in Visual Analogue Scales (VAS)
VAS is for assessment of RLS-associated pain. The patient was asked "How severe was your RLS associated pain in legs or arms during the past week?". No pain:0; very worst pain:10
Time frame: Baseline and 6 weeks of treatment
| Milestone | Pramipexole | Placebo |
|---|---|---|
| Started | 203 | 103 |
| Completed | 189 | 91 |
| Not completed | 14 | 12 |
| Withdrew: Not treated | 1 | 0 |
| Withdrew: Adverse event | 6 | 1 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 5 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Other reason not defined above | 4 | 5 |
The IRLS was a 10-item self patient's rating scale for assessing severity of restless legs syndrome symptoms with each item ranging from 0 (no symptoms) to 4 (very severe symptoms). The total IRLS score ranges from 0 (no symptoms) to 40 (worst possible symptoms).
| Score on a scale | Pramipexole | Placebo |
|---|---|---|
| The Change From Baseline to Week 6 in the Total Score of Restless Legs Syndrome Rating Scale for Severity of the International Restless Legs Syndrome Study Group (IRLS). | -15.87 ± 0.66 | -11.35 ± 0.92 |
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved)and 2 (much improved.
| Proportion of Patients | Pramipexole | Placebo |
|---|---|---|
| The Proportion of Patients With Clinical Global Impressions -Improvement Scale (CGI-I) Assessment of "Much Improved" and "Very Much Improved" | 0.819 | 0.543 |
responders is defined as the total score in IRLS changed ≥ 50%from baseline calculated in the full analysis set population.
| Proportion of Patients | Pramipexole | Placebo |
|---|---|---|
| The Proportion of IRLS Responders | 0.738 | 0.489 |
PGI was a one-question scale with 7 degrees to assess patient's overall condition, ranging from very much better to very much worse. The responder are defined as patients with their assessment of "much better" or "very much better".
| Proportion of participants | Pramipexole | Placebo |
|---|---|---|
| The Proportion of Patient Global Impression(PGI) Responders | 0.686 | 0.435 |
The ESS is a self-administered instrument to assess the patients likelihood of falling asleep in various activities of daily living; the maximum score is 24 indicating a very high level of daytime sleepiness and a high likelihood of falling asleep.
| Proportion of Patients | Pramipexole | Placebo |
|---|---|---|
| The Proportion of Patients With Epworth Sleepiness Scale (ESS) Categorised >10 | 0.108 | 0.054 |
RLS-6 rating scales comprises 6 questions Satisfaction of sleep is one of the 6 questions. The patient should give a rate between 0 (none/Not at all) to 10 (very severe) for the satisfaction of sleep.
| Score on a scale | Pramipexole | Placebo |
|---|---|---|
| the Mean Change From Baseline to Week 6 in Satisfaction of Sleep at Night of RLS-6 Rating Scales | -4.52 ± 0.21 | -3.04 ± 0.3 |
RLS-6 rating scales comprises 6 questions. The severity of RLS at time of falling sleep is one of the 6 questions. The patient should give a rate between 0 (none/Not at all) to 10 (very severe) for the severity of RLS at time of falling sleep
| Score on a scale | Pramipexole | Placebo |
|---|---|---|
| The Mean Change From Baseline in the Severity of RLS at Time of Falling Sleep of RLS-6 Rating Scales. | -4.9 ± 0.21 | -3.53 ± 0.28 |
RLS-6 rating scales comprises 6 questions. The severity of RLS during the night is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the severity of RLS during the night.
| Score on a scale | Pramipexole | Placebo |
|---|---|---|
| The Mean Change From Baseline in the Severity of RLS During the Night of RLS-6 Rating Scales. | -4.68 ± 0.21 | -3.32 ± 0.29 |
RLS-6 rating scales comprises 6 questions. The severity of RLS during the test at day is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the severity of RLS during the rest at day.
| Score on a scale | Pramipexole | Placebo |
|---|---|---|
| The Mean Change From Baseline in the Severity of RLS During the Rest at Day of RLS-6 Rating Scales. | -2.9 ± 0.17 | -2.36 ± 0.23 |
RLS-6 rating scales comprises 6 questions. The severity of RLS during the activities at day is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the severity of RLS during the activity at day.
| Score on a scale | Pramipexole | Placebo |
|---|---|---|
| The Mean Change From Baseline in the Severity of RLS During the Activities at Day of RLS-6 Rating Scale | -0.93 ± 0.12 | -0.61 ± 0.16 |
RLS-6 rating scales comprises 6 questions. The intensity of tiredness and sleepiness at day is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the intensity of tiredness and sleepiness at day.
| Score on a scale | Pramipexole | Placebo |
|---|---|---|
| The Mean Change From Baseline in the Intensity of Tiredness and Sleepiness at Day of RLS-6 Rating Scale | -2.96 ± 0.16 | -2.25 ± 0.22 |
VAS is for assessment of RLS-associated pain. The patient was asked "How severe was your RLS associated pain in legs or arms during the past week?". No pain:0; very worst pain:10
| Score on a scale | Pramipexole | Placebo |
|---|---|---|
| The Change From Baseline in Visual Analogue Scales (VAS) | 2.6 ± 2.5 | 3.9 ± 3 |
Collected over 6 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pramipexole | — | 3/202 (1.5%) | 81/202 (40.1%) |
| Placebo | — | 0/103 (0%) | 25/103 (24.3%) |
| Event | Pramipexole | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 1/202 | 0/103 |
| InjuryInjury, poisoning and procedural complications | 1/202 | 0/103 |
| Transient ischaemic attackNervous system disorders | 1/202 | 0/103 |
| Event | Pramipexole | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 35/202 | 9/103 |
| SomnolenceNervous system disorders | 28/202 | 9/103 |
| NauseaGastrointestinal disorders | 26/202 | 8/103 |
| HeadacheNervous system disorders | 20/202 | 2/103 |
| InsomniaPsychiatric disorders | 4/202 | 6/103 |
Safety Set, all randomized patients that received treatment
| Age, Continuous(Years) | Pramipexole | Placebo | Total |
|---|---|---|---|
| Mean | 56.46 ± 11.88 | 56.86 ± 11.89 | 56.6 ± 11.87 |
| Sex: Female, Male(Participants) | Pramipexole | Placebo | Total |
|---|---|---|---|
| Female | 122 | 75 | 197 |
| Male | 80 | 28 | 108 |
The record gives a start of Apr 2008, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2010, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pramipexole